Murray Korc
Overview
Explore the profile of Murray Korc including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
7248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jeon C, Arain M, Korc M, Kozarek R, Phillips A
Curr Opin Gastroenterol
. 2024 Jun;
40(5):431-438.
PMID: 38935270
Purpose Of Review: The burdens of pancreatic ductal adenocarcinoma (PDAC) and acute pancreatitis are increasing globally. We reviewed current literature on whether acute pancreatitis is a causal factor for PDAC...
2.
Korc M
Clin Cancer Res
. 2023 Apr;
29(13):2348-2350.
PMID: 37099035
Several approaches for overcoming immunotherapy resistance in pancreatic and colorectal cancer syngeneic models were assessed using heparin and immunotherapy. Beneficial responses were attributed to heparin-induced vascular normalization, ensuing CD8+ T-cell...
3.
Hart P, Papachristou G, Park W, Dyer A, Chinchilli V, Afghani E, et al.
Pancreas
. 2022 Oct;
51(6):568-574.
PMID: 36206460
Acute pancreatitis (AP) is a disease characterized by an acute inflammatory phase followed by a convalescent phase. Diabetes mellitus (DM) was historically felt to be a transient phenomenon related to...
4.
Principe D, Kamath S, Korc M, Munshi H
Pharmacol Ther
. 2022 Jan;
236:108111.
PMID: 35016920
Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for several malignancies. While the use of single-agent or combined ICIs has achieved acceptable disease control rates in a variety of...
5.
Principe D, Underwood P, Korc M, Trevino J, Munshi H, Rana A
Front Oncol
. 2021 Aug;
11:688377.
PMID: 34336673
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival time of 10-12 months. Clinically, these poor outcomes are attributed to several factors, including late stage at the...
6.
Principe D, Korc M, Kamath S, Munshi H, Rana A
Cancer Lett
. 2021 Feb;
504:1-14.
PMID: 33549709
Immunotherapy has revolutionized cancer treatment in the last decade, and strategies to re-activate cytotoxic immunity are now standard of care in several malignancies. Despite rapid advances in immunotherapy for most...
7.
Sasaki N, Gomi F, Yoshimura H, Yamamoto M, Matsuda Y, Michishita M, et al.
Cancers (Basel)
. 2020 Oct;
12(10).
PMID: 33066597
Fibroblast growth factor receptor 4 (FGFR4), one of four tyrosine kinase receptors for FGFs, is involved in diverse cellular processes. Activation of FGF19/FGFR4 signaling is closely associated with cancer development...
8.
9.
Hart P, Andersen D, Mather K, Castonguay A, Bajaj M, Bellin M, et al.
Pancreas
. 2018 Oct;
47(10):1239-1243.
PMID: 30325863
Pancreatogenic diabetes mellitus is most commonly the result of chronic pancreatitis but can also occur secondary to pancreatic cancer. The early identification of pancreatogenic diabetes and distinction from the more...
10.
Simpson R, Yip-Schneider M, Wu H, Fan H, Liu Z, Korc M, et al.
Am J Surg
. 2018 Oct;
217(3):425-428.
PMID: 30293901
Background: IPMNs are cystic pancreatic lesions with variable malignant potential. Thrombospondin-2 (THBS2)-an endogenous, anti-angiogenic matrix glycoprotein-may modulate tumor progression. We hypothesized that circulating levels of THBS2 could aid in preoperative...